Compare · NVO vs SEPN
NVO vs SEPN
Side-by-side comparison of Novo Nordisk A/S (NVO) and Septerna Inc. (SEPN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SEPN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.82B, about 165.9x SEPN ($1.11B).
- Over the past year, NVO is down 34.2% and SEPN is up 252.6% - SEPN leads by 286.9 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 3 for SEPN).
- NVO has more recent analyst coverage (25 ratings vs 9 for SEPN).
- Company
- Novo Nordisk A/S
- Septerna Inc.
- Price
- $41.18+6.93%
- $24.68-1.10%
- Market cap
- $183.82B
- $1.11B
- 1M return
- +13.32%
- +2.05%
- 1Y return
- -34.24%
- +252.64%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 5
- 3
- Recent ratings
- 25
- 9
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S
Latest SEPN
- SEC Form 4 filed by Bhatt Elizabeth
- Septerna Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism
- SEC Form S-3ASR filed by Septerna Inc.
- SEC Form S-8 filed by Septerna Inc.
- SEC Form 10-K filed by Septerna Inc.
- Septerna Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
- Chief People Officer Shaikhly Samira exercised 70,453 shares at a strike of $1.84 and sold $1,979,838 worth of shares (70,453 units at $28.10) (SEC Form 4)
- SEC Form 144 filed by Septerna Inc.